Explore
Validate
Learn
Western blot
Immunocytochemistry
ImmunoprecipitationAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Other assay [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-27322 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- VHL Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant protein fragment
- Description
- Recommended positive controls: Myc-DDK-tagged VHL-transfected 293T. Predicted reactivity: Mouse (93%), Rat (91%), Dog (95%), Bovine (96%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 0.6 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references Disturbed Flow Increases UBE2C (Ubiquitin E2 Ligase C) via Loss of miR-483-3p, Inducing Aortic Valve Calcification by the pVHL (von Hippel-Lindau Protein) and HIF-1α (Hypoxia-Inducible Factor-1α) Pathway in Endothelial Cells.
miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma.
Fernandez Esmerats J, Villa-Roel N, Kumar S, Gu L, Salim MT, Ohh M, Taylor WR, Nerem RM, Yoganathan AP, Jo H
Arteriosclerosis, thrombosis, and vascular biology 2019 Mar;39(3):467-481
Arteriosclerosis, thrombosis, and vascular biology 2019 Mar;39(3):467-481
miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma.
Zhang WC, Wells JM, Chow KH, Huang H, Yuan M, Saxena T, Melnick MA, Politi K, Asara JM, Costa DB, Bult CJ, Slack FJ
Nature metabolism 2019 Apr;1(4):460-474
Nature metabolism 2019 Apr;1(4):460-474
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemistry-Immunofluorescence analysis of VHL was performed in HeLa cells fixed in 4% paraformaldehyde at RT for 15 min. Green: VHL Polyclonal Antibody (Product # PA5-27322) diluted at 1:500. Red: phalloidin, a cytoskeleton marker. Scale bar = 10 µm.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 miR-147b-VHL axis mediates drug-tolerance through impaired VHL activity. a , Left, gene candidates predicted for miR-147b by the TargetScan tool were shown in signaling pathways enriched for gefitinib-tolerance in PC9 single-cell clones in fig. 1f . Right, qRT-PCR analysis for the predicted gene candidates for miR-147b in H1975 cells with miR-147b knockdown compared with scrambled control. n=3 independent biological replicates. b , Left, computational prediction of RNA duplex formation between miR-147b and the 3'UTR (untranslated region) of VHL mRNA. Mutations generated within the 3'UTR for the luciferase assay are shown in red. Right, dual-luciferase reporter assay in miR-147b-overexpressing AALE cells. The Firefly luciferase and Renilla luciferase activities were measured 48 hours post co-transfection with miR-147b or control vector and wild-type (WT) or mutant (Mut) VHL 3'UTR. n=3 independent biological replicates. c , Western blot analysis and quantification of VHL in miR-147b-overexpressing AALE cells. beta-Actin was used as loading control. n=3 independent biological replicates. d , qRT-PCR analysis for fold change of hypoxia gene expression in AALE cells with miR-147b overexpression relative to scrambled control (147b/Scr) and cells with co-overexpression of miR-147b and VHL relative to scrambled control (147b+VHL/Scr). ACTB was used as endogenous control. n=3 independent biological replicates. e , Fractional viability of HCC827 cells treated with vehicle, osi
